KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Change in Acquisitions & Divestments (2022)

ClearPoint Neuro recorded quarterly Change in Acquisitions & Divestments of $12.0 million in Q4 2022.

ClearPoint Neuro's Change in Acquisitions & Divestments history runs 1 years deep, the most recent figure standing at $12.0 million for Q4 2022.

  • In Q4 2022, Change in Acquisitions & Divestments changed N/A year-over-year to $12.0 million; the TTM figure through Sep 2024 stood at $12.0 million (changed N/A YoY), while the FY2023 annual figure was $10.0 million, down 16.67% from the prior year.
  • Change in Acquisitions & Divestments came in at $12.0 million for Q4 2022 at ClearPoint Neuro.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $12.0 million in Q4 2022 to a low of $12.0 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 ClearPoint Neuro 375.84 Mn 340.24 Mn 7.76 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 12.00 Mn
Dec 31, 2022 12.00 Mn